Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors

Ipsen secures exclusive global rights for development and commercialization of STRO-003, an antibody-drug conjugate, completing the final stages of pre-clinical development STRO-003 targets ROR1, a clinically validated antibody drug conjugate (ADC) target STRO-003 has shown robust monotherapy efficacy and potential for a differentiated safety profile in preclinical development in solid tumors and hematological malignancies1 PARIS…
Read More



Get A FREE Copy Of My Special Report
“Can Your Retirement Survive” Today!
There's Absolutely $0 Cost To You!
We Even Pay For Shipping & Handling!

This post contains affiliate links. If you use these links to buy something we may earn a commission. Thanks.”

You May Also Like